CD33
CD33
CD33 (pronounced "C-D-thirty-three") is a transmembrane receptor expressed on cells of myeloid lineage. It is also known as SIGLEC-3 (sialic acid binding Ig-like lectin 3) and gp67 and is a member of the SIGLEC (sialic acid-binding immunoglobulin-type lectins) family.
Etymology
The term "CD33" is derived from the term "Cluster of Differentiation 33". The "CD" nomenclature was established at a series of international workshops intended to classify monoclonal antibodies against leukocyte surface antigens.
Function
CD33 is an inhibitory receptor that plays a role in modulating immune responses. It is involved in cell-cell interactions and cellular adhesion. CD33 is also a target for certain therapies, such as gemtuzumab ozogamicin, a drug used in the treatment of acute myeloid leukemia (AML).
Related Terms
- SIGLEC: A family of cell surface proteins that bind sialic acid. CD33 is a member of this family.
- Monoclonal antibodies: Antibodies that are made by identical immune cells that are all clones of a unique parent cell. CD33 can be targeted by these antibodies.
- Acute myeloid leukemia (AML): A type of cancer in which the bone marrow makes abnormal myeloblasts, red blood cells, or platelets. CD33 is often expressed in AML cells.
See Also
External links
- Medical encyclopedia article on CD33
- Wikipedia's article - CD33
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski